Mini review · 2016
Short communicationPublished 2020
Approaches to immunomodulation in relapsing multiple sclerosis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The BCD-132 and BCD-054 (JSC BIOCAD, Russia) are novel immunomodulating therapeutic options for relapsing form of multiple sclerosis (MS) treatment. The BCD-054 is a conjugate of recombinant human interferon β1a and linear polyethylene glycol (PEG) with a molecular weight of 30kDA. Such conjugation decreases renal clearance, increases half-life of drug and, consequently, allows to prolong the duration of action and reduce the frequency of injections compared with non-pegylated forms of interferon. The interim 20-week results of BCD-054 III phase study showed significant reduction in brain MRI disease activity on PEG interferon β1a therapy compared with placebo. It was proven, what two studied doses of BCD-054 superior to placebo for the primary efficacy endpoint represented by combined unique active (CUA) lesion counts. Assessment of clinical performance demonstrated the reduction of relapse rate: BCD-054 180 μg - 10, 62%, BCD-054 240 μg - 6,14%, low dose interferon β1a (LIB) - 15,93%, placebo - 15,79%. Another potential treatment of MS is BCD-132, an innovative the 3rd generation humanized afukosylated anti-CD20 antibodies. It has increased affinity for FcγRllla, thereby effectively induces antibody-dependent cytotoxicity and antibody dependent phagocytosis. Direct strictly specific effect of BCD-132 on B lymphocyte in a wide range of doses (100-1000 mg) was established by dynamic assessment of such cells lever in phase I clinical trial after intravenous administration of increasing doses in two dosage regimens. The obtained data shows that BCD-132 has an expected pharmacodynamic effect of long-term depletion of CD19+ and CD20+ B cell lineage and an acceptable safety profile when used to treat patients with MS in all studied doses.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 2014
Benefit-Risk of Immunomodulators in Multiple Sclerosis. Alemtuzumab and Next?
Review article · 2016
Immunomodulation of Glatiramer Acetate in Multiple Sclerosis
Commentary · 30 Dec 2024
Comparative Effectiveness of Rituximab and Cladribine in Relapsing-Remitting Multiple Sclerosis: Insights from Target Trial Emulation
Article · 25 Jan 2023
Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective
More from this journal
The newest in Acta Psychopathologica.
Article · 24 Feb 2025
Investigating the Linkage of Anxiety and Depression to the Feeling of Anguish
Article · 17 Jan 2025
Cognitive Behavioral Therapy for Treating Complex Anxiety Disorders in Adolescent Populations: A Comprehensive Systematic Review and Meta-Analysis
Article · 30 Dec 2024
Mental Health Disorders in the Digital Age: Challenges and Solutions
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalActa Psychopathologica
- SubjectNeuroscience & Neurology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Alexey Boyko”
